



256~261.舒尼替尼诱导耐药鼻咽癌CNE2/DDP细胞表达NKG2DLs的机制[J].黄宇贤,王杨,李玉华,杨玉莲,赵同峰,何庆梅,卢惠芳,贺艳杰,黄睿,郭坤元.中国肿瘤生物治疗杂志,2010,17(3).

舒尼替尼诱导耐药喉癌CNE2/DDP细胞表达NKG2DLs的机制 点此下载全文

黄宇贤 王杨 李玉华 杨玉莲 赵同峰 何庆梅 卢惠芳 贺艳杰 黄睿 郭坤元

基金项目：国家自然科学基金资助项目（No. 30973454）；广东省自然科学基金重点项目（No. 9251051501000007）

DOI : 10.3872/i.issn.1007-385X.2010.3.003

## 摘要：

目的：初步探讨舒尼替尼诱导高、低表达ABCG2(ATP binding cassette superfamily G member 2)分子的耐药鼻咽癌CNE2/DDP细胞(简称ABCG2<sup>high</sup> CNE2/DDP细胞, ABCG2<sup>low</sup> CNE2/DDP细胞)中NKG2D配体(natural killer group 2 member D ligands, NKG2DLs)表达的分子机制。方法：Caspase 8活化试剂盒和线粒体膜电位法分别检测NK细胞处理后ABCG2<sup>high</sup> CNE2/DDP细胞和ABCG2<sup>low</sup> CNE2/DDP细胞caspase 8活化水平和线粒体膜电位。RT PCR检测舒尼替尼处理前后两种CNE2/DDP细胞DNA损伤修复系统相关信号分子mRNA的表达。结果：CNE2/DDP细胞+NK细胞组中两种CNE2/DDP细胞caspase 8活性均明显增强；舒尼替尼处理后的ABCG2<sup>low</sup> CNE2/DDP细胞+NK细胞组和ABCG2<sup>high</sup> CNE2/DDP细胞+NK细胞组中caspase 8的活性是处理前的2~2.5倍( $P < 0.01$ )。舒尼替尼预处理后，CNE2/DDP细胞和NK细胞共培养体系中两种CNE2/DDP细胞的线粒体膜电位分别为(76.58±2.32)%和(73.11±1.93)%，较舒尼替尼处理前明显降低( $P < 0.05$ )。舒尼替尼可上调两种CNE2/DDP细胞中ATR、CHK1和CHK2 mRNA的表达，并诱导P53和NF-κB mRNA的表达。结论：舒尼替尼可能通过激活DNA损伤修复系统相关信号分子和NF-κB的表达，诱导耐药鼻咽癌CNE2/DDP细胞NKG2DLs的表达，同时经由死亡受体信号通路和线粒体信号通路增强NK细胞诱导的肿瘤细胞凋亡。

关键词：舒尼替尼 鼻咽肿瘤 NKG2D配体 自然杀伤细胞 DNA损伤

Mechanism of sunitinib inducing NKG2DLs expressions in multidrug resistant nasopharyngeal carcinoma CNE2/DDP cells Download Fulltext

HUANG Yu-xian WANG Yang LI Yu-hua YANG Yu-lian ZHAO Tong-feng HE Qing-mei LU Hui-fang HE Yan-Jie HUANG Rui GUO Kun-yuan

Fund Project:Project supported by the National Natural Science Foundation of China (No. 30973454), and the Key Program of Natural Science Foundation of Guangdong Province (No. 9251051501000007)

### Abstract:

Objective: To investigate the mechanism by which sunitinib induces up regulation of NKG2D ligands(NKG2DLs) expressions in nasopharyngeal carcinoma CNE2/DDP cells with high or low ABCG2 expression (ABCG2 high CNE2/DDP cells or ABCG2 low CNE2/DDP cells). Methods: Caspase 8 activity and mitochondrial membrane potential were detected by caspase 8 activity kit and mitochondrial membrane potential assay kit in ABCG2 high CNE2/DDP cells or ABCG2 low CNE2/DDP cells after co cultured with NK cells. Expressions of signal molecules involved in DNA damage and repair system were detected by RT PCR in ABCG2 high CNE2/DDP cells and ABCG2 low CNE2/DDP cells before and after sunitinib treatment. Results: Caspase 8 activities in ABCG2 high CNE2/DDP cells and ABCG2 low CNE2/DDP cells were significantly increased after co cultured with NK cells. After treatment with sunitinib, caspase 8 activities in the co culture system were 1-1.5 times higher than those in the untreated ABCG2 high and ABCG2 low CNE2/DDP cells ( $P < 0.01$ ). Sunitinib inhibited mitochondrial membrane potentials of ABCG2 high and ABCG2 low CNE2/DDP cells in NK cell co culture systems, with the potentials in two kinds of sunitinib treated CNE2/DDP cells decreased to  $(76.58 \pm 2.32)\%$  and  $(73.11 \pm 1.93)\%$ , respectively, which were markedly lower than those in the untreated ABCG2 high and ABCG2 low CNE2/DDP cells ( $P < 0.05$ ). Sunitinib could increase mRNA expressions of ATR, CHK1 and CHK2 in ABCG2 high and ABCG2 low CNE2/DDP cells, and induce P53 and NF  $\kappa$ B mRNA expressions. Conclusion: Sunitinib can up regulate NKG2DLs expressions in CNE2/DDP cells by activating signaling molecules related to DNA damage and repair system and NF  $\kappa$ B, and enhance NK cell induced apoptosis of tumor cells through death receptor and mitochondrial pathways.

**Keywords:** sunitinib, nasopharyngeal neoplasms, natural killer groups 2 member D ligand (NKG2DL), natural killer cell, DNA damage